中美合作中医药防治肿瘤建良好机制,刘延东作重要批示

2017-08-22 吴潇湘 中国中医

近年来,中美双方在中医药防治肿瘤方面建立良好合作机制,产出一批成果。国务院副总理刘延东对此作重要批示。8月17日,2017年国际中医药肿瘤联盟研讨会在广东省广州市召开,会议以“凝聚、创新、共进(共促中医药肿瘤国际化进程)”为主题,旨在通过联盟搭建的平台发挥海内外专家优势,提升肿瘤防治水平,针对影响中医药防治肿瘤水平的关键问题,加强临床与基础创新研究,深化学术交流与合作,共推中医防治肿瘤的国际化。

近年来,中美双方在中医药防治肿瘤方面建立良好合作机制,产出一批成果。国务院副总理刘延东对此作重要批示。8月17日,2017年国际中医药肿瘤联盟研讨会在广东省广州市召开,会议以“凝聚、创新、共进(共促中医药肿瘤国际化进程)”为主题,旨在通过联盟搭建的平台发挥海内外专家优势,提升肿瘤防治水平,针对影响中医药防治肿瘤水平的关键问题,加强临床与基础创新研究,深化学术交流与合作,共推中医防治肿瘤的国际化。

刘延东在对中美双方在中医药防治肿瘤合作的批示中指出,多年来,在中美两国政府部门支持下,中国中医科学院与美国国立癌症研究所等科研机构在防治肿瘤方面开展务实合作,在机理研究、疾病防治、人才培养等方面取得了积极进展。刘延东强调,传统医学和现代医学在防治重大疾病方面各有所长、互有优势,要积极推动中医药交流合作和协同创新,促进中医药与现代医学互学互鉴、融合发展,创新肿瘤防治模式,提高临床诊疗效果,充分发挥中医药在防治重大疾病、应对全球卫生挑战中的作用,推动中医药“走出去”,让民族瑰宝更好地造福人类健康。

国家卫生计生委副主任、国家中医药管理局局长王国强出席研讨会早餐会时指出,刘延东副总理的重要批示,为中美中医药防治肿瘤进一步深化合作,推进互学互鉴、融合发展指明了方向。

一要开放包容,推动中医药与西医药融合发展。中美中医药防治肿瘤合作机制的实践证明,中医药在重大疾病防治中具有独特优势,可以为肿瘤的治疗提供一条中西医协同、中西医融合的发展路径。要坚持以临床疗效为根本,以病理病机、作用机制、药品研发等为重点,开出肿瘤防治的中西医结合“处方”。

二要坚持原创,研发代表大国水平的健康产品。充分发挥中医药在治未病、重大疾病治疗和疾病康复中的作用,充分运用现代科学技术的新方法、新手段、新成果,产出一批类似“青蒿素”的具有原创性、标志性的代表大国水平的健康产品,让民族瑰宝造福人类健康。

三要人才为先,合理培育高素质中医药人才。发挥中美双方的教育优势、科研优势和平台优势,构建以中医药科研人员培养为重点、临床医师短期进修为基础的人才培养格局,培养一支用国际语言讲好中医药防治肿瘤故事的高素质人才队伍。

四要完善机制,打造高水平对话交流平台。进一步完善联盟相关章程,做好内部组织机构建设,确保联盟工作的有效开展。深化学术交流与合作,挖掘联盟各成员的不同优势,不断创新合作机制与模式,实现资源共享,优势互补,共同促进提升肿瘤防治水平。

五要加强文化交流,促进科研与文化的融合。加强东西方文化交流,增进文化认同融合,才能夯实中医药理论方法体系及科学价值的认识基础,才能进一步深化中医药科技合作,创新中医药转化机制,共同服务人类健康。

会上,来自美国、新加坡、澳大利亚及中国的专家学者交流了在中医药肿瘤研究领域的最新进展。

国际中医药肿瘤联盟(ICCMC)是由中国中医科学院广安门医院、中国中医科学院肿瘤研究所与美国国立癌症研究所补充与替代医学办公室(OCCAM)共同于2015年成立,是由在恶性肿瘤中医药研究领域的著名科研机构、政府、制药企业的专家学者组成的国际性合作交流平台,旨在共同推动中医药防治肿瘤研究科学化、国际化进程,使全球的肿瘤患者受益于中医药的治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1810936, encodeId=f93718109368a, content=<a href='/topic/show?id=43fc8664341' target=_blank style='color:#2F92EE;'>#良好机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86643, encryptionId=43fc8664341, topicName=良好机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Apr 15 02:43:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669161, encodeId=e946166916156, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon May 14 18:43:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923219, encodeId=01391923219d6, content=<a href='/topic/show?id=3cc7319e030' target=_blank style='color:#2F92EE;'>#刘延东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31970, encryptionId=3cc7319e030, topicName=刘延东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Sun Oct 22 15:43:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409027, encodeId=8a07140902e80, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Aug 24 00:43:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236337, encodeId=678123633ee7, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Aug 23 10:28:41 CST 2017, time=2017-08-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1810936, encodeId=f93718109368a, content=<a href='/topic/show?id=43fc8664341' target=_blank style='color:#2F92EE;'>#良好机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86643, encryptionId=43fc8664341, topicName=良好机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Apr 15 02:43:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669161, encodeId=e946166916156, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon May 14 18:43:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923219, encodeId=01391923219d6, content=<a href='/topic/show?id=3cc7319e030' target=_blank style='color:#2F92EE;'>#刘延东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31970, encryptionId=3cc7319e030, topicName=刘延东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Sun Oct 22 15:43:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409027, encodeId=8a07140902e80, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Aug 24 00:43:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236337, encodeId=678123633ee7, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Aug 23 10:28:41 CST 2017, time=2017-08-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1810936, encodeId=f93718109368a, content=<a href='/topic/show?id=43fc8664341' target=_blank style='color:#2F92EE;'>#良好机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86643, encryptionId=43fc8664341, topicName=良好机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Apr 15 02:43:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669161, encodeId=e946166916156, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon May 14 18:43:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923219, encodeId=01391923219d6, content=<a href='/topic/show?id=3cc7319e030' target=_blank style='color:#2F92EE;'>#刘延东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31970, encryptionId=3cc7319e030, topicName=刘延东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Sun Oct 22 15:43:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409027, encodeId=8a07140902e80, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Aug 24 00:43:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236337, encodeId=678123633ee7, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Aug 23 10:28:41 CST 2017, time=2017-08-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1810936, encodeId=f93718109368a, content=<a href='/topic/show?id=43fc8664341' target=_blank style='color:#2F92EE;'>#良好机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86643, encryptionId=43fc8664341, topicName=良好机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Apr 15 02:43:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669161, encodeId=e946166916156, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon May 14 18:43:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923219, encodeId=01391923219d6, content=<a href='/topic/show?id=3cc7319e030' target=_blank style='color:#2F92EE;'>#刘延东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31970, encryptionId=3cc7319e030, topicName=刘延东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Sun Oct 22 15:43:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409027, encodeId=8a07140902e80, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Aug 24 00:43:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236337, encodeId=678123633ee7, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Aug 23 10:28:41 CST 2017, time=2017-08-23, status=1, ipAttribution=)]
    2017-08-24 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1810936, encodeId=f93718109368a, content=<a href='/topic/show?id=43fc8664341' target=_blank style='color:#2F92EE;'>#良好机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86643, encryptionId=43fc8664341, topicName=良好机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Apr 15 02:43:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669161, encodeId=e946166916156, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon May 14 18:43:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923219, encodeId=01391923219d6, content=<a href='/topic/show?id=3cc7319e030' target=_blank style='color:#2F92EE;'>#刘延东#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31970, encryptionId=3cc7319e030, topicName=刘延东)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6142500060, createdName=12498710m11暂无昵称, createdTime=Sun Oct 22 15:43:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409027, encodeId=8a07140902e80, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Aug 24 00:43:00 CST 2017, time=2017-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=236337, encodeId=678123633ee7, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Wed Aug 23 10:28:41 CST 2017, time=2017-08-23, status=1, ipAttribution=)]
    2017-08-23 明天会更好!

    谢谢分享谢谢分享

    0

相关资讯

郗小星被调查事件回顾:大国利益浇灭国际科研合作火种

(郗小星教授,图片摘自sciencemag.com) 2015年5月21日破晓时分,美国华裔物理学家郗小星醒来时发现他的家(宾州费城)被一群武装调查人员包围了。当他赶忙打开门探问发生了什么事时。这些调查员掏出手枪,宣布郗小星因受控将被逮捕。当时,他的妻子与刚上中学的女儿看到郗小星衣衫不整地被手铐,被强行带走的一幕让他们感到十分地害怕。 郗小星当时是费城Temple大学物理系的代理主任,同时